Long-term outcomes of liver transplantation using grafts from donors with active hepatitis B virus replication: a multicenter cohort study
10.4174/astr.2023.104.4.183
- Author:
Sujin GANG
1
;
YoungRok CHOI
;
Boram LEE 2
;
Kyung Chul YOON
;
Su young HONG
;
Sanggyun SUH
;
Eui Soo HAN
;
Suk Kyun HONG
;
Hae Won LEE
;
Jai Young CHO
;
Nam-joon YI
;
Kwang-Woong LEE
;
Kyung-Suk SUH
Author Information
1. Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Annals of Surgical Treatment and Research
2023;104(4):183-194
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Liver grafts from donors with HBV infection contributed to expanding the donor pool under the hepatitis B immunoglobulin and antiviral agents (nucleos(t)ide analogues) in the HBV-endemic area. We report long-term outcomes of liver transplantations (LTs) using grafts from donors with active or chronic HBV infection.
Methods:Overall, 2,260 LTs performed in 3 major hospitals in Seoul from January 2000 to April 2019 were assessed for inclusion. Twenty-six grafts (1.2%) were obtained from HBsAg (+), HBeAb (+), or HBcAb (+) donors, and recipient outcomes were retrospectively reviewed. Donor and recipient demographics and transplantation outcomes were analyzed.
Results:Sixteen deceased donor LTs were performed using active HBsAg (+) grafts. Ten other LTs were sourced from 10 living donors. There was no significant difference in survival in patients who received deceased donor LTs compared with that in those who underwent LT with non–hepatitis virus-infected grafts. Fourteen patients who were followed up for >5 years were stable, and no difference in hepatocellular carcinoma recurrence rate was observed 5 years after transplantation between transplants from donors with and those without HBV.
Conclusion:Considering long-term outcomes, liver grafts from donors with active HBV replication can be safely used for LT.
